In a report released today, Rick Wise from Stifel Nicolaus maintained a Hold rating on Tandem Diabetes (NASDAQ: TNDM), with a price target of $34. The company’s shares opened today at $38.04, close to its 52-week high of $38.40.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 14.9% and a 74.1% success rate. Wise covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Obalon Therapeutics Inc, and Boston Scientific Corp.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tandem Diabetes with a $31.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.40 and a one-year low of $2.14. Currently, Tandem Diabetes has an average volume of 2.81M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
